– USA, MA – Solid Biosciences Inc. (NASDAQ:SLDB) today announced that Martin Freed, M.D., F.A.C.P., a biopharmaceutical expert with more than 25 years of industry experience, has joined its Board of Directors. Additionally, Gilad Hayeem, Solid’s Co-Founder, Director and President, has retired from his role as President and from Solid’s Board to pursue other activities. Ilan Ganot, Co-Founder and Chief Executive Officer, has now also assumed the role of President.
“I want to thank Gilad for his many significant contributions to Solid and service to the Duchenne muscular dystrophy community,” said Andrey Zarur, Ph.D., Co-Founder and Chairman of the Board of Solid Biosciences. “As a member of our founding team, he played an instrumental role in the creation and strategic direction of the company. While I am saddened by his departure, I am excited to continue to collaborate with him as a thought leader as we jointly address this horrific disease. We wish him the best of luck in his future endeavors.”
Dr. Zarur continued, “Dr. Freed’s breadth of hands-on experience in helping companies advance innovative products through clinical development and approval is impressive. He brings this expertise to Solid, and we are delighted to welcome him to our Board.”
“Gilad was the first to support our vision that we can and should aggressively pursue a plan to bring meaningful therapies to all patients with Duchenne muscular dystrophy,” said Ilan Ganot, Co-Founder and Chief Executive Officer of Solid Biosciences. “His compassion, dedication and hands-on involvement helped make Solid what it is today.”
Dr. Martin Freed brings to Solid more than 25 years of strategic development and operational expertise from across the biopharmaceutical and life sciences industries. As a seasoned drug development executive and life sciences entrepreneur, his experience spans from Phase 1 drug development through to post-registration clinical development and medical affairs programming across numerous therapeutic areas.
Dr. Freed has held senior leadership positions with various biopharmaceutical companies, most recently as Co-Founder and Chief Medical Officer of Civitas Therapeutics, Inc., which was acquired by Acorda Therapeutics Inc. in 2014. Prior to Civitas, he held leadership positions at Adnexus Therapeutics, Inc., Vitae Pharmaceuticals, Inc. and SmithKline Beecham Pharmaceuticals/GlaxoSmithKline. Dr. Freed has been published in more than 40 peer reviewed manuscripts, four book chapters and more than 90 abstracts related to an array of drug development and translational medicine programs. Currently, Dr. Freed also holds Board positions with Dicerna Pharmaceuticals, Inc. and Sojournix, Inc.
Dr. Freed performed his internal medicine residency at Temple University Hospital and nephrology fellowship at Yale-New Haven Hospital.
About Solid Biosciences
Solid Biosciences is a life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). Founded by those touched by the disease, Solid is a center of excellence for DMD, bringing together experts in science, technology and care to drive forward a portfolio of candidates that have life-changing potential. Currently, Solid is progressing programs across four scientific platforms: Corrective Therapies, Disease-Modifying Therapies, Disease Understanding and Assistive Devices.
For more information : https://www.solidbio.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
